Updated:
Napo Pharmaceuticals
Napo Pharmaceuticals operates as a wholly owned subsidiary of San Francisco-based Jaguar Health, focusing on proprietary plant-based human...
Napo Pharmaceuticals
Napo Pharmaceuticals operates as a wholly owned subsidiary of San Francisco-based Jaguar Health, focusing on proprietary plant-based human gastrointestinal pharmaceuticals sourced from rainforest plants. The firm's science is rooted in ethnobotany, studying traditional knowledge of local peoples in the Amazon basin. The company develops and commercializes two botanical drugs, crofelemer (NP-303) and NP-300, both extracted and purified from the Croton lechleri tree. Crofelemer, discovered through ethnobotanical research, targets moderate to severe diarrhea; NP-300 is a novel candidate for bacterial, viral, and parasitic infections including Vibrio cholerae. The tree sap supply comes from fast-growing pioneer trees widespread in Peru, Colombia, Ecuador, and Bolivia. Napo Pharmaceuticals is structured as a single-family office serving the capital generated by the Jaguar Health enterprise. The firm maintains offices in San Francisco and New York, though total team size and AUM remain undisclosed. No recent operational events from the last 24 months are publicly documented. A structural differentiator is the firm's singular focus on plant-based pharmaceuticals via sustainable rainforest harvesting, a model that ties drug development directly to conservation and local community knowledge. This narrow therapeutic focus on gastrointestinal conditions, combined with an ethnobotanical discovery approach, distinguishes Napo from broader biotech family offices.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, New York, United States
Additional offices
New York
Sector focus
Frequently asked questions
Who runs investment decisions at Napo Pharmaceuticals?
Napo Pharmaceuticals is a wholly owned subsidiary of Jaguar Health, so investment decisions likely reside with Jaguar Health's management. No named investment professionals are publicly listed for Napo as a standalone entity (per firm website).
How does Napo Pharmaceuticals source proprietary deal flow?
Napo does not function as a traditional investment firm; its deal flow is driven by in-house drug development rather than external sourcing. The firm discovers drugs through ethnobotanical research, studying traditional plant uses in the Amazon (per firm website).
Is Napo Pharmaceuticals structured as a single family office or does it operate more like a venture firm?
Napo Pharmaceuticals is structured as a wholly owned subsidiary within the Jaguar Health corporate structure, effectively functioning as a single-family office for the capital generated by that enterprise. It does not operate as a venture firm or external asset manager.
Does Napo Pharmaceuticals participate in fund commitments or only direct deals?
Napo Pharmaceuticals does not appear to make fund commitments or direct external investments; its focus is entirely on developing its own proprietary drug candidates crofelemer and NP-300 (per firm website).
What investment stages does Napo Pharmaceuticals typically target?
Napo Pharmaceuticals targets no external investment stages; it is a drug development company commercializing its own pipeline products. The firm has not disclosed any external investment activities.
Which sectors does Napo Pharmaceuticals explicitly avoid?
Napo Pharmaceuticals does not publish a list of avoided sectors. Its activities are confined to gastrointestinal pharmaceuticals derived from rainforest plants.
Where does the underlying wealth come from?
The underlying wealth comes from the commercial activities of Jaguar Health, Napo's parent company. Specific wealth origin details for the principals are not publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: